CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the development of antisense oligonucleotide (ASO) therapeutics for the treatment of cancer pain. Q-State will subsequently be eligible for an additional $1 million in grant funding based on successful completion of certain program milestones.
Funded as part of the NIH HEAL InitiativeSM, the grant supports Q-State’s efforts to pursue analgesic treatment paradigms beyond those associated with opioids. The company is currently advancing ASO candidates targeting Nav1.7, Nav1.8, or both channels using the company’s AI-enabled computational neuroscience technology. In addition to cancer pain, these ASO candidates also have potential applicability in the treatment of a variety of other moderate-to-severe pain states.
This grant was awarded by the National Institute of Cancer of the National Institutes of Health under Award Number R44CA247110. The content of the press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Q-State Biosciences
Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, Massachusetts. We integrate advanced human neuronal models, proprietary determinative measurement engineering and powerful AI/machine learning to discover and develop novel therapeutics for epilepsy, pain, and other disorders of the CNS. For more information, please visit www.qstatebio.com.
